{"analyses":[{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.73","estimateComment":"Hazard ratios are estimated using a Pike estimator.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.62"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"14.7","value":"12.1"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"8.1","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"352"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the interval of time between the date of randomization and the first documented occurrence of disease progression or death due to any cause. PFS for investigator-assessed response was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression was defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dabrafenib 150 milligrams (mg) orally twice daily (BID) and Trametinib 2 mg orally once daily until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib Plus Trametinib"},{"description":"Vemurafenib 960 mg orally BID until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Vemurafenib"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population.","reportingStatus":"POSTED","timeFrame":"From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)","title":"Progression-Free Survival (PFS), as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}